Molecular and clinical characterization of TIM-3 in glioma through 1,024 samples

Guanzhang Li, Zheng Wang, Chuanbo Zhang, Xing Liu, Jinquan Cai, Zhiliang Wang, Huimin Hu, Fan Wu, Zhaoshi Bao, Yanwei Liu, Lian Zhao, Tingyu Liang, Fan Yang, Ruoyu Huang, Wei Zhang, and Tao Jiang

*Beijing Neurosurgical Institute, Capital Medical University, Beijing, China; bChinese Glioma Genome Atlas Network (CGGA); cDepartment of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China; dDepartment of Neurosurgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, China; eDepartment of Neurosurgery, University Medical Center Düsseldorf, Düsseldorf, Germany; fBeijing Institute for Brain Disorders Brain Tumor Center, Beijing, China; gChina National Clinical Research Center for Neurological Diseases, Beijing, China

ABSTRACT

Background: Researches on immunotherapy of glioma has been increasing exponentially in recent years. However, autoimmune-like side effects of current immune checkpoint blockade hindered the clinical application of immunotherapy in glioma. The discovery of the TIM-3, a tumor-specific immune checkpoint, has shed a new light on solution of this dilemma. We aimed at investigating the role of TIM-3 at transcriptome level and its relationship with clinical practice in glioma.

Methods: A cohort of 325 glioma patients with RNA-seq data from Chinese Glioma Genome Atlas (CGGA project) was analyzed, and the results were well validated in TCGA RNA-seq data of 699 gliomas. R language was used as the main tool for statistical analysis and graphical work.

Results: TIM-3 was enriched in glioblastoma (the most malignant glioma) and IDH-wildtype glioma. TIM-3 can act as a potential marker for mesenchymal molecular subtype according to TCGA transcriptional classification scheme in glioma. TIM-3 was closely related to immune functions in glioma, especially T cell mediated immune response to tumor cell and T cell mediated cytotoxicity directed against tumor cell target. Moreover, TIM-3 and PD-L1 played almost exactly the same inflammatory activation functions in glioma. Clinically, high expression of TIM-3 was an independent indicator of poor prognosis.

Conclusion: The expression of TIM-3 is closely related to the pathology and molecular pathology of glioma. Meanwhile, in glioma TIM-3 plays a specific role in T cell tumor immune response. Therefore, TIM-3 is a promising target for immunotherapeutic strategies, providing an alternative treatment when glioma gains resistance to antibodies of PD-1/PD-L1.

Introduction

Glioma represents the most common and malignant brain tumor in adults, characterized by a high recurrence rate and high fatality rate. Despite multimodal conventional therapy, including neurosurgical resection and radiotherapy with concomitant and adjuvant alkylating agent temozolomide chemotherapy, glioma remains a leading cause of death in human cancer. Within decades, amounts of researches on molecular markers and molecular targeted drugs produced very limited effect in prolonging life expectancies of glioma patients. The discovery of intracranial lymphatic system has brought a new theoretical basis and new hope for brain tumor immunotherapy.

Driven by the success of immune checkpoint blockade in other cancers, researches on immunotherapy of glioma has increased exponentially in the past few years. However, most glioma have been proved to be refractory to current immunotherapies. This has raised our interest in finding novel immune checkpoints directly targeting tumor cells in glioma.

T cell immunoglobulin domain and mucin domain 3 (TIM3) is a membrane protein selectively expressed on interferon-gamma-secreting CD4+ T helper 1 (Th1) and CD8+ T cytotoxic (Tc1) cells. Emerging data suggest that Tim-3 takes a center stage in T cell exhaustion by triggering cell death: T cells fail to exert effective functions such as cytotoxicity and cytokine secretion in response to antigen and tumor cell stimulation. TIM-3, as a key immune checkpoint in tumor-induced immune suppression, exhibits several unique features that make it an intriguing candidate for the next wave of therapies in cancer.

As a novel immune checkpoint, TIM-3 is gaining more and more attention in both solid and hematologic malignancies. However, we reviewed the current evidence and failed to find a single comprehensive report about TIM-3 in glioma. Taking advantage of Chinese Glioma Genome Atlas (CGGA) data set, we gathered RNA-seq data of 325 glioma samples to take an integrative investigation of TIM-3 in glioma. Moreover, our
findings were well validated in another RNA-seq data set of 699 gliomas obtained from TCGA network (http://cancergenome.nih.gov). This is the first integrative study characterizing TIM-3 expression in whole grade glioma molecularly and clinically. And we believe that TIM-3 will be a hot ticket in glioma immunotherapy.

Patients and methods

Patients and samples

This study was approved by the Beijing Tiantan Hospital institutional review board (IRB), and wrote informed consent was obtained from each patient. Only samples with greater than 80% tumor cells were selected. Transcriptome sequencing data of glioma samples were from CGGA generating with Illumina Hiseq platform. Overall survival was estimated from the date of diagnosis to the date of either death or last follow-up. Methods to detect IDH mutation state has been described in our previous study.11 The Cancer Genome Atlas (TCGA) mRNA-seq database was downloaded from public databases (https://tcga-data.nci.nih.gov/tcga/tcgaDownload.jsp). The primary GSC (glioma stem-like cells) gene expression array data set was downloaded from GSE67089.

Gene set variation analysis (GSVA) analysis

After Spearman correlation analysis, gene ontology (GO) analysis of the most correlated genes was constructed by Heatmap. The GO genset was downloaded from AmiGO 2 Web portal (http://amigo.geneontology.org/amigo/landing). Inflammatory-related metagenes has been described in our previous study.5

Statistical analysis

The prognostic value of TIM-3 was estimated by Kaplan–Meier analysis and Cox proportional hazard model analysis using SPSS statistical software (version 19). Other statistical computations and figures drawing were performed with several packages (ggplot2, pheatmap, pROC and corrgram) in the statistical software environment R, version 3.3.2 (http://www.r-project.org). For all statistical methods, \( p < 0.05 \) was considered as significant difference.

Results

TIM-3 was enriched in glioblastoma and IDH-wildtype glioma

To characterize the expression pattern of TIM-3 in glioma, we examined the RNA-sequencing data of glioma from CGGA and TCGA database. Compared to WHO grade II and grade III glioma, glioblastoma (WHO IV) showed the highest TIM-3 expression in CGGA database (Fig. 1A). This result was well validated in TCGA RNA-seq data (Fig. 1C). This finding indicated that TIM-3 check point related immune responses were more prevalent in IDH wildtype glioma. Moreover, we found that TIM-3 was specifically expressed in GSC cells (Fig. S2), which was also found in acute myeloid leukemia.17

TIM-3 was a potential marker for mesenchymal molecular subtype glioma

To find out the molecular expression pattern of TIM-3, we asked the distribution of TIM-3 in different molecular subtypes defined by TCGA network.18 When compared with other three subtypes respectively, TIM-3 was significantly upregulated in mesenchymal subtype in CGGA cohort as well as in TCGA cohort (Figs. 2A and C). To further validate this finding, ROC curves for TIM-3 expression and mesenchymal subtype of all grade glioma were performed. Surprisingly, area under the curve (AUC) were up to 90.5% and 88.9% in CGGA and TCGA data set, respectively (Figs. 2B and D). These results suggested that TIM-3 was highly specifically expressed in mesenchymal subtype glioma. Based on these findings, we inferred that TIM-3 may play important biologic functions in glioma. To validate our hypothesis, biologic function analyses need to be performed.
A detailed list of these genes was shown in Table S1. Above analysis found that TIM-3 was positively correlated with most immune responses and negatively correlated with a small number of immune responses in glioma. A thorough study of this result may reveal the important role of TIM-3 in gliomas.

**The relationship between TIM-3 and T cell immunity**

TIM-3 promotes tumor progression in a variety of tumors by inhibiting T cell immune function.\(^1\)\(^9\)\(^20\) Whether it has the same functions in gliomas remain an enigma. To elucidate the relationship between TIM-3 and T cell immune in glioma, GSVA analysis was performed. As shown in Figs. 4A and B, TIM-3 was positively correlated with T-helper 1/2 type immune response, T-helper 1/2 cell cytokine production and natural killer cell mediated cytotoxicity directed against tumor cell target. Meanwhile, it was negatively correlated with T cell mediated immune response to tumor cell and T cell mediated cytotoxicity directed against tumor cell target. Importantly, this result can be verified mutually in CGGA and TCGA databases. This also confirmed that TIM-3 played an inhibitory role in T cell immune to tumor in glioma. The special immune function of TIM-3 revealed the mechanism of this gene in glioma.

**The relationship between TIM-3 and inflammatory activities**

As revealed above, TIM-3 also played an important role in the inflammatory response in glioma. We used the method described previously to specifically analyze the role of TIM-3 in the glioma inflammatory response.\(^5\) To our surprise, TIM-3 showed exactly similar pattern to inflammation activities as PD-L1 we reported earlier\(^5\) (Figs. 4C and D). Both genes were positively associated with HCK, LCK and MHC-I, but were negatively associated with IgG. These results suggested that TIM-3 and PD-L1 play almost exactly the same inflammatory activation functions (they were macrophages and T cells signaling transduction suppressors, but not much involved in B lineage related immune responses) in glioma. This finding was consistent with the above results and further confirmed the important immune function of TIM-3 in glioma.

**TIM-3 predicted worse survival in glioma**

As TIM-3 showed robust negative relationship with T cell tumor immune response, we additional analysis the prognostic value of TIM-3. We analyzed the prognosis of a total of 1,024 glioma patients by Kaplan–Meier method. Similar with most malignancies, overexpression of TIM-3 predicted significantly poor overall survival in both CGGA and TCGA databases (Figs. 5A and B). Furthermore, Cox regression analysis was performed additionally, verifying the independence of the clinical prognostic significance of TIM-3 in glioma. In the above two databases, it was showed that TIM-3, Age at Diagnosis, WHO Grade, KPS Score and IDH Status were significantly associated with overall survival. On multivariate analysis, the expression of TIM-3 was also a significant factor after adjusting for the clinical factors mentioned above (Table 1 and Table S2). These findings indicated that TIM-3 predicted poor prognosis in gliomas.
glioma due to suppressive effect on T-cell-related immune response, especially T cell immune to tumor.

Discussion

Glioma is one of the highly fatal diseases that affects human health severely. Aside from temozolomide, for decades, no major breakthrough was achieved to improve the prognosis of glioma patients. Therefore, new therapeutic approaches are urgently needed. In recent years, as a novel therapeutic approach of glioma patients, immunotherapy has shown a promising prospect. At present, researches on the field of neural tumor immunotherapy are mainly focus on CTLA-4 and PD-1/PD-L1 blockade. However, since the autoimmune-like side effects of current immune checkpoint blockade, immunotherapy is difficult to be widely applied. This is the so-called “Cancer Immunology at the Crossroads.” Fortunately, at this critical moment, people discovered a novel immune checkpoint receptor-TIM-3. This novel immune checkpoint exhibits several unique advantages that make it an intriguing candidate for immunotherapy of glioma in the future.

Here, we analyzed the TIM-3 expression in the RNA-seq data of 1,024 glioma patients. As expected, TIM-3 expression was significantly upregulated in higher malignant pathological type gliomas. Moreover, we also found that high expression of TIM-3 was highly enriched in the phenotype of known malignant molecules, such as IDH wildtype state, mesenchymal...
phenotype and glioma stem cells. All these results indicated that TIM-3 expression was associated with more malignant biologic process as other solid and hematologic malignancies.\textsuperscript{25,26} It is most likely that these malignant biologic behaviors have contributed to tumor recurrence and therapy resistance. Revealing mechanism of TIM-3 in glioma may be the key to triumphing over this deadly disease.

Through an in-depth analysis of the biologic functions of TIM-3 in glioma, we found that TIM-3 played an important role in the glioma immune response, especially in tumor-induced immune suppression. This special effect of TIM-3 has also been observed in other tumors.\textsuperscript{7,8,20} This may be attributed to the unique presence of TIM-3 Tregs in tumor tissue, which was a unique advantage over other immune checkpoints.\textsuperscript{27-29} Furthermore, another unique advantage of TIM3 was that intracellular tail of TIM-3 did not contain any immunoreceptor tyrosine-based inhibition motifs (ITIM) or immunoreceptor tyrosine-based switch motifs (ITSM).\textsuperscript{30} These advantages effectively avoided the major deficiencies of current immunotherapy and highlighted its value in glioma immunotherapy. As an immune inhibitory receptor, suppressing the inflammatory response and autoimmunity are the natural property of TIM-3.\textsuperscript{31,32} We found that TIM-3 played almost exactly the same role in inflammatory response as PD-L1 in glioma. Together, these data indicated that TIM-3 and PD-L1 played a synergistic role in tumor inflammatory response to promote the development of a severe dysfunctional phenotype in T cells in glioma as reported in other cancers.\textsuperscript{33,34} Thus, theoretically, antibodies derived to block the stimulation of TIM-3 should have the same effect as PD-L1 suppression. Multiple preclinical and clinical targeting TIM-3 have yielded consistent results with the theory in various tumors, particularly melanoma and non-small-cell lung cancer.\textsuperscript{35,36} A research published in the latest issue of \textit{Clin Cancer Res} reported that TIM-3/PD-1 co-blockade was more effective than either TIM-3 or PD-1 blockade alone at restoring inflammation activation and improving survival time from glioma-bearing murine.\textsuperscript{37} This gratifying discovery provided a reliable support for our research. Furthermore, TIM-3 will also have a profound impact on studies of glioma.

Table 1. Univariate and multivariate analysis of clinical prognostic parameters in CGGA Dataset.

| Variable          | Univariate analysis | Multivariate analysis |
|-------------------|---------------------|-----------------------|
|                   | HR (95% CI)         | p value               | HR (95% CI)         | p value               |
| TIM-3 expression  | 1.038 (1.027–1.050) | <0.0001               | 1.023 (1.007–1.040) | 0.005                 |
| Age at diagnosis  | 1.038 (1.023–1.054) | <0.0001               | 0.991 (0.969–1.014) | 0.452                 |
| WHO grade         | 3.477 (2.716–4.452) | <0.0001               | 2.752 (1.961–3.862) | <0.0001               |
| KPS score         | 0.972 (0.962–0.982) | <0.0001               | 0.972 (0.960–0.984) | <0.0001               |
| IDH mutation      | 0.228 (0.158–0.329) | <0.0001               | 0.763 (0.433–1.344) | 0.348                 |

Figure 4. TIM-3-related T cell immunity and inflammatory activities in glioma. (A, B) The relationship between TIM-3 and T cell immunity in CGGA and TCGA data set. (C, D) The relationship between TIM-3 and inflammatory activities in glioma. The correlation between TIM-3 and other functions was analyzed by Pearson correlation analysis. ns, * and **** indicate no statistical difference, \( p < 0.05 \) and \( p < 0.0001 \), respectively. GO:0042088: T-helper 1 type immune response, GO:0042092: T-helper 2 type immune response, GO:2000556: positive regulation of T-helper 1 cell cytokine production, GO:2000553: positive regulation of T-helper 2 cell cytokine production, GO:0002860: positive regulation of natural killer cell mediated cytotoxicity directed against tumor cell target, GO:0002842: positive regulation of T cell mediated immune response to tumor cell, GO:0002852: regulation of T cell mediated cytotoxicity directed against tumor cell target.
stem cells if it can be a therapeutic target of glioma stem cells. This hypothesis has already been validated in acute myeloid leukemia stem cells.\textsuperscript{38} Whether it is the same case in glioma stem cells or not, still need further studies. Collectively, these data strongly support the potential of TIM-3 blockade for the immunotherapy of glioma.

The future of glioma treatment most likely resides in combinatorial approaches, with administration of conventional treatments (surgery, radiochemotherapy) and immunotherapy complement each other. Our works will greatly promote the immunotherapy of glioma into a new era.

**Disclosure of potential conflicts of interest**

No potential conflicts of interest were disclosed.

**Acknowledgments**

We thank Ms. Yuling Yang and Kun Yao for tissue sample collection and clinical data retrieval.

**Funding**

This work was supported by grants from National Key Research and Development Plan (No. 2016YFC0902500), National Natural Science Foundation of China (No. 81672479, 81502495, 81502606), Beijing Youth Talent Project (2015000021233ZK28), Beijing Nova Program (No. xx2014B062) and Fok Ying Tung Education Foundation (No. 141032).

**ORCID**

Jinquan Cai \[http://orcid.org/0000-0002-6773-3546\]

**References**

1. Van Meir EG, Hadijanpazis CG, Norden AD, Shu HK, Wen PY, Olson JJ. Exciting new advances in neuro-oncology: The avenue to a cure for malignant glioma. CA Cancer J Clin 2010; 60(3):166-93; PMID:20445506; https://doi.org/10.3322/caac.20069

2. Jiang T, Mao Y, Ma W, Mao Q, You Y, Yang X, Jiang C, Kang C, Li X, Chen L et al. GGCG clinical practice guidelines for the management of adult diffuse gliomas. Cancer Lett 2016; 375(2):263-73; PMID:26966000; https://doi.org/10.1016/j.clet.2016.01.024

3. Louveau A, Smirnov I, Keyes TJ, Eccles JD, Rouhani SJ, Peske JD, Derecki NC, Castle D, Mandell JW, Lee K et al. Structural and functional features of central nervous system lymphatic vessels. Nature 2015; 523(7561):337-41; PMID:26030524; https://doi.org/10.1038/nature14432

4. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott FD, Powlesley JD, Carvajal RD, Sosman JA, Atkins MB et al. Safety, activity, and immune correlates of anti-CD1 antibody in cancer. N Engl J Med 2012; 366(26):2443-54; PMID:22658127; https://doi.org/10.1056/NEJMoA120690

5. Wang Z, Zhang C, Liu X, Wang Z, Sun L, Li G, Liang J, Hu H, Liu Y, Zhang W et al. Molecular and clinical characterization of PD-L1 expression at transcriptional level via 976 samples of brain glioma. Oncocommunications 2016; 5(11):e1196310; PMID:27999734; https://doi.org/10.1080/2162402X.2016.1196310

6. Zhu C, Anderson AC, Kuchroo VK. TIM-3 and its regulatory role in immune responses. Curr Top Microbiol Immunol 2011; 350:1-15; PMID:20700701; https://doi.org/10.1007/82_2010_84

7. Das M, Zhu C, Kuchroo VK. Tim-3 and its role in regulating anti-tumor immunity. Immunol Rev 2017; 276(1):97-111; PMID:28258697; https://doi.org/10.1111/imr.12520

8. Mattei F, Schiavoni G, TIM-3 as a molecular switch for tumor escape from innate immunity. Front Immunol 2012; 3:418; PMID:22331620; https://doi.org/10.3389/fimmu.2012.00418

9. Romero D. Immunotherapy: PD-1 says goodbye, TIM-3 says hello. Nat Rev Clin Oncol 2016; 13(4):202-3; PMID:26977783; https://doi.org/10.1038/nrclinonc.2016.40

10. Anderson AC. TIM-3: An emerging target in the cancer immunotherapy landscape. Cancer Immunol Res 2014; 2(5):393-8; PMID:24795351; https://doi.org/10.1158/2326-6066.CIR-14-0039

11. Yan W, Zhang W, You G, Bao Z, Wang Y, Liu Y, Kang C, You Y, Wang L, Jiang T. Correlation of IDH1 mutation with clinicopathologic factors and prognosis in primary glioblastoma: a report of 118 patients from China. PLoS One 2012; 7(1):e30339; PMID:22291938; https://doi.org/10.1371/journal.pone.0030339

12. Xu L, Huang Y, Tan L, Yu W, Chen D, Lu C, He J, Wu G, Liu X, Zhang Y. Increased Tim-3 expression in peripheral NK cells predicts a poorer prognosis and Tim-3 blockade improves NK cell-mediated cytotoxicity in human lung adenocarcinoma. Int Immunopharmacol 2015; 29(2):655-41; PMID:2648847; https://doi.org/10.1016/j.intimp.2015.09.017

13. Zhou E, Huang Q, Wang J, Fang C, Yang L, Zhu M, Chen J, Chen L, Dong M. Up-regulation of Tim-3 is associated with poor prognosis of patients with colon cancer. Int J Clin Exp Pathol 2015; 8(7):8018-27; PMID:26339368

14. Yuan J, Jiang B, Zhao H, Huang Q. Prognostic implication of TIM-3 in clear cell renal cell carcinoma. Neoplasia 2014; 61(1):35-40; PMID:24195506; https://doi.org/10.4149/neo_2014_006

15. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009; 360(8):765-73; PMID:19228619; https://doi.org/10.1056/NEJMoA0808710

16. Wang HY, Tang K, Liang TY, Zhang WZ, Li JY, Wang W, Hu HM, Li MY, Wang HQ, He XZ et al. The comparison of clinical and biological characteristics between IDH1 and IDH2 mutations in gliomas. J Exp Clin Cancer Res 2016; 35:86; PMID:27245979; https://doi.org/10.1186/s13046-016-0362-7

17. Jan M, Chao MP, Cha AC, Alizadeh AA, Gentles AJ, Weissman IL, Majeti R. Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker. Proc Natl Acad Sci U S A 2011; 108(12):5009-14; PMID:21383193; https://doi.org/10.1073/pnas.1007511108

18. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRα, IDH1, EGFR, and NF1. Cancer Cell 2010; 17(1):98-110; PMID:20929521; https://doi.org/10.1016/j.ccr.2009.12.020

19. Sabatos CA, Chakravarti S, Cha E, Schubart A, Sánchez-Fueyo A, Zheng XX, Goyle AJ, Strom TB, Freeman GJ, Kuchroo VK. Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance. Nat Immunol 2003; 4(11):509-14; PMID:12906579; https://doi.org/10.1038/nature03454

20. Cai J, Yu YF, Wu ZL, Dong Q, Li MY, Olson JC, Rabrinowitz YM, Wang LH, Sun Y. Tim-3 expression represents dysfunctional tumor infiltrating T cells in renal cell carcinoma. World J Urol 2016; 34(4):561-7; PMID:26253654; https://doi.org/10.1007/s00345-015-1656-7

21. Wang J, Su HK, Zhao HF, Chen ZP, To SS. Progress in the application of molecular biomarkers in gliomas. Biochem Biophys Res Commun 2015; 465(1-2):475-83; PMID:26253473; https://doi.org/10.1016/j.bbrc.2014.11.004 10.1016/j.bbrc.2015.05.019

22. Han SJ, Zygourakis C, Lim M, Pasa AT. Immunotherapy for glioma: Promises and challenges. Neurosurg Clin N Am 2012; 23(3):375-7; PMID:22748649; https://doi.org/10.1016/j.nec.2012.05.001

23. Belcaid Z, Phallen JA, Zeng J, See AP, Mathios D, Gottschalk C, Nicholas S, Kellett M, Ruzevick J, Jackson C et al. Focal radiation therapy combined with 4-1BB activation and CTLA-4 blockade yields long-term survival and a protective antigen-specific memory response in a
murine glioma model. PLoS One 2014; 9(7):e101764; PMID:25013914; https://doi.org/10.1371/journal.pone.0101764

24. Zhang L, Zhang Z, Liu Y, Yue Y, Parney I. Programmed death-ligand 1 (PD-L1) may play a role in malignant glioma infiltration. Med Hypotheses 2015; 83(2):127-9; PMID:25936667; https://doi.org/10.1016/j.mehy.2015.04.009

25. Wang Z, Yin N, Zhang Z, Zhang Y, Zhang G, Chen W. Upregulation of T-cell immunoglobulin and Mucin-Domain Containing-3 (Tim-3) in monocytes/macrophages associates with gastric cancer progression. Immunol Invest 2017; 46(2):134-148; PMID:27911104; https://doi.org/10.1080/08820139.2016.1229790

26. Zhou Q, Munger ME, Veenstra RG, Weigel BJ, Hirashima M, Munn DH, Murphy WJ, Azuma M, Anderson AC, Kuchroo VK et al. Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood 2011; 117(17):4501-10; PMID:21385853; https://doi.org/10.1182/blood-2010-10-310425

27. Sakuishi K, Ngiow SF, Sullivan JM, Teng MW, Kuchroo VK, Smyth MJ, Anderson AC. TIM3(+)FOXP3(+) regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer. Oncoimmunology 2013; 2(4):e23849; PMID:23734331; https://doi.org/10.4161/onci.23849

28. Cipolletta D, Feuerer M, Li A, Kamei N, Lee J, Shoelson SE, Benoist C, Mathis D. PPAR-γ is a major driver of the accumulation and phenotype of adipose tissue Treg cells. Nature 2012; 486(7404):549-53; PMID:22722857; https://doi.org/10.1038/nature11132

29. Burzyn D, Kuswanto W, Kolodin D, Shadrach JL, Cerletti M, Jang Y, Sefk E, Tan TG, Wagers AJ, Benoist C et al. A special population of regulatory T cells potentiates muscle repair. Cell 2013; 155(6):1282-95; PMID:24315098; https://doi.org/10.1016/j.cell.2013.10.054

30. Rangachari M, Zhu C, Sakuishi K, Xiao S, Karman J, Chen A, Angin M, Wakeham A, Greenfield EA, Sobel RA et al. Bat3 promotes T cell responses and autoimmune by repressing Tim-3–mediated cell death and exhaustion. Nat Med 2012; 18(9):1394-400; PMID:22863785; https://doi.org/10.1038/nm.2871

31. Zhang Y, Ma CJ, Wang JM, Ji XJ, Wu XY, Moorman JP, Yao ZQ. Tim-3 regulates pro- and anti-inflammatory cytokine expression in human CD14+ monocytes. J Leukoc Biol 2012; 91(2):189-96; PMID:21844165; https://doi.org/10.1189/jlb.0110591

32. Ramel MC, Tosello BJ, Canale FP, Mena HA, Negrotto S, Gastman B, Gruppi A, Acosta Rodriguez EV, Montes CL. Tumor-induced senescent T cells promote the secretion of pro-inflammatory cytokines and angiogenic factors by human monocytes/macrophages through a mechanism that involves Tim-3 and CD40L. Cell Death Dis 2014; 5: e1507; PMID:25375372; https://doi.org/10.1038/cddis.2014.451

33. Wang S, Cao C, Piao H, Li Y, Tao Y, Zhang X, Zhang D, Sun C, Zhu R, Wang Y et al. Tim-3 protects decidual stromal cells from toll-like receptor-mediated apoptosis and inflammatory reactions and promotes Th2 bias at the maternal-fetal interface. Sci Rep 2015; 5:9013; PMID:25757669; https://doi.org/10.1038/srep09013

34. Li X, Chen G, Li Y, Wang R, Wang L, Lin Z, Gao X, Feng J, Ma Y, Shen B et al. Involvement of T cell Ig Mucin-3 (Tim-3) in the negative regulation of inflammatory bowel disease. Clin Immunol 2010; 134(2):169-77; PMID:19913460; https://doi.org/10.1016/j.clim.2009.09.012

35. Fourcade J, Sun Z, Benalloua M, Guillaume P, Luescher IF, Sander C, Kirkwood JM, Kuchroo V, Zarour HM. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med 2010; 207 (10):2175-86; PMID:20819923; https://doi.org/10.1084/jem.20100637

36. Gao X, Zhu Y, Li G, Huang H, Zhang G, Wang F, Sun J, Yang Q, Zhang X, Lu B. Tim-3 expression characterizes regulatory T cells in tumor tissues and is associated with lung cancer progression. PLoS One 2012; 7(2):e30676; PMID:22363469; https://doi.org/10.1371/journal.pone.0030676

37. Kim JE, Patel MA, Mangraviti A, Kim ES, Theodros D, Velarde E, Liu A, Sankey EW, Tam A, Xu H et al. Combination therapy with anti-PD-1, anti-TIM-3, and focal radiation results in regression of murine gliomas. Clin Cancer Res 2017; 23(1):124-136; PMID:27358487; https://doi.org/10.1158/1078-0432.CCR-15-1535

38. Kikushige Y, Shima T, Takayanagi S, Urata S, Miyamoto T, Iwasaki H, Takenaka K, Teshima T, Tanaka T, Inagaki Y et al. TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells. Cell Stem Cell 2010; 7(6):708-17; PMID:21112565; https://doi.org/10.1016/j.stem.2010.11.014